【摘要】 目的　分析单纯 11三体异常与恶性血液病的临床、血液学、免疫学及预后的关系。方法　对所有病例采用骨髓细胞直接法或短期培养法制备染色体标本 ,采用R显带技术进行核型分析。对 5例患者作了白血病细胞表面免疫标记分析 ,10例急性髓系白血病 (AML)患者接受HA(高三尖杉酯碱、阿糖胞苷 )为主的方案治疗 ,并随访治疗结果和生存期。结果　在 176 3例恶性髓系血液病患者中发现 11例有单纯 11三体异常 ,发生率为 0 .6 %。疾病类型为AML 10例 (M2 6例 ,M52例 ,M1 和M4 各 1例 ) ,骨髓增生异常综合征 1例。 10例患者均无肝、脾肿大 (1例资料不详 )。 5例白血病细胞免疫标志检测显示CD34 (+)、CD1 3(+)和CD33(+)。随访的 10例患者总缓解率为 4 0 % ,中位生存期为 10个月。结论　单纯 11三体异常主要见于急性髓系白血病 ,以M2 最多见 ,其预后不良。更多还原

【Abstract】 Objective To evaluate the association between isolated trisomy 11 and the clinical, hematologi cal, immunological, prognostic aspects in hematological malignancies. Methods Bone marrow cell cytogenetic analysis was performed by direct method and/or 24 h culture method. RHG banding was used for karyotype analysis. Immunophenotype analysis was carried out by flow cytometry. Ten patients with acute myeloid leukemia (AML) were treated with HA regimen chemotherapy and followed up. Results The isolated trisomy 11 was found in 11 of 1?763 hematological malignancies cases (0.6%). The diagnoses included 10 AML (6 M 2, 2 M 5, 1 M 1, 1 M 4), and 1 myelodysplastic syndromes. Ten of them have no hepatosplenomegaly. The immunophenotypical analysis of leukemia cells showed positive for CD 13 , CD 33 and CD 34 in 5 cases. Follow up data were available in 10 cases. The complete remission rate was 40% with a median survival of 10 months. Conclusion The isolated trisomy 11 was mainly seen in AML, especially in M 2 subtype. Their prognosis was poor.更多还原